• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (5): 711-716.DOI: 10.3969/j.issn.1671-2587.2026.05.007

• 临床输血 • 上一篇    下一篇

实体肿瘤患者围手术期输注冰冻解冻去甘油红细胞的安全性与有效性分析*

李津杞, 夏莉莉, 刘佳艺, 周梅, 王星怡, 顾海慧   

  1. 中国人民解放军海军军医大学第一附属医院输血科,上海 200433
  • 收稿日期:2026-09-02 修回日期:2026-09-22 出版日期:2026-10-20 发布日期:2026-11-11
  • 通讯作者: 顾海慧,主要从事临床输血与细胞治疗方面研究,(E-mail)haihuigu@126.com。
  • 作者简介:李津杞,主要从事临床输血方面研究,(E-mail)ljq_421@163.com。共同第一作者:夏莉莉,主要从事临床输血方面研究,(E-mail)2441215443@qq.com。

Analysis on the Safety and Efficacy of Perioperative Transfusion of Frozen-Thawed Deglycerolized Red Blood Cells in Patients with Solid Tumors

LI Jinqi, XIA Lili, LIU Jiayi, ZHOU Mei, WANG Xingyi, GU Haihui   

  1. Blood Transfusion Department, First Affiliated Hospital of Naval Military Medical University, Shanghai 200433
  • Received:2026-09-02 Revised:2026-09-22 Online:2026-10-20 Published:2026-11-11

摘要: 目的 评估实体肿瘤患者输注冰冻解冻去甘油红细胞(frozen-thawed deglycerolized red blood cells, FTDRBC)的安全性特征,探讨其在不同临床情境下的应用价值及对围手术期血液保障的意义。方法 回顾性分析2025年6月—2026年6月100例实体肿瘤患者的输血资料。根据FTDRBC首次输注时机分为术中出血组(n=75)与贫血纠正组(n=25)。以输血周期为分析单位,收集输注前后血红蛋白(hemoglobin, Hb)变化、单位输注效率(ΔHb/U)、72 h后续红细胞需求率及总红细胞暴露量。安全性评价包括肝肾功能、凝血功能动态变化及输血相关不良反应。采用配对Wilcoxon检验分析输注前后Hb变化,Mann-Whitney U检验进行组间比较,卡方检验比较组间后续需求率。结果 术中出血组基线Hb为71(61,83)g/L,输注后24 h ΔHb中位数为7(2,14)g/L(Z=-5.29,P<0.001);贫血纠正组基线Hb为68(55,80.3)g/L,24 h ΔHb为7(3.5,10)g/L(Z=-3.99,P<0.001)。在72 h内未追加红细胞的纯净亚组中,两组48 h ΔHb分别为8(-0.75,18.75)与8(0.5,19.5)g/L(Z=-0.079,P=0.937),72 h ΔHb分别为8.5(-5,15.75)与12(3.5,26.5)g/L(Z=-1.099,P=0.272)。两组72 h后续红细胞需求率分别为47%(35/75)与32%(8/25),差异无统计学意义(χ2=1.646,P=0.200)。多因素线性回归显示储存天数与24 h ΔHb/U无显著相关(P=0.520)。安全性方面,输注前后TBil、Cr、AST、ALT及APTT、TT、FIB、PT、D-二聚体的差异均无统计学意义;100例患者中未观察到输血相关不良反应。结论 实体肿瘤患者输注FTDRBC后呈现明确的Hb回升效应,两种情境下ΔHb无统计学差异,且72 h后续输血需求可控。长期储存(中位928 d)未影响输注效率。未见肝肾功能及凝血功能损伤证据,未观察到输血相关不良反应。在血液资源紧张或稀有血型储备情境下,FTDRBC在实体肿瘤患者围手术期输血中具有良好的安全性和有效性。

关键词: 冰冻解冻去甘油红细胞, 实体肿瘤, 患者血液管理, 输血安全, 围手术期贫血

Abstract: Objective To evaluate the safety profile of transfusing frozen-thawed deglycerolized red blood cells (FTDRBCs) in patients with solid tumors, and to explore its application value in different clinical scenarios and significance for perioperative blood support. Methods A retrospective analysis was conducted on transfusion data from 100 patients with solid tumors treated between June 2025 and June 2026. Patients were divided into the intraoperative bleeding group (n=75) and the anemia correction group (n=25) based on the timing of the first FTDRBC transfusion.Using the transfusion episode as the analytical unit, we collected data on Hb before and after transfusion, unit transfusion efficiency (ΔHb/U), 72-hour subsequent red blood cell requirement rate, and total red blood cell exposure. Safety evaluation included dynamic changes in liver and renal function, coagulation parameters, and transfusion-related adverse reactions. The paired Wilcoxon test was used to analyze Hb changes before and after transfusion, the Mann-Whitney U test for between-group comparisons, and the chi-square test for comparing subsequent requirement rates between groups. Results In the intraoperative bleeding group, the baseline Hb was 71 (61, 83) g/L, and the median ΔHb at 24 h post-transfusion was 7 (2, 14) g/L (Z=-5.29, P<0.001); in the anemia correction group, the baseline Hb was 68 (55, 80.3) g/L, and the 24 h ΔHb was 7 (3.5, 10) g/L (Z=-3.99, P<0.001). In the transfusion-free subgroup without additional red blood cell transfusions within 72 h, the 48 h ΔHb in the two groups were 8 (-0.75, 18.75) and 8 (0.5, 19.5) g/L, respectively (Z=-0.079, P=0.937), and the 72 h ΔHb were 8.5 (-5, 15.75) and 12 (3.5, 26.5) g/L, respectively (Z=-1.099, P=0.272). The 72-hour subsequent red blood cell requirement rates in the two groups were 47% (35/75) and 32% (8/25), respectively, with no statistically significant difference (χ2=1.646, P=0.200). Multivariate linear regression showed that there was no significant correlation between storage days and 24 h ΔHb/u (P=0.520). Regarding safety, no statistically significant differences were observed in TBil, Cr, AST, ALT, APTT, TT, FIB, PT or D-dimer before and after transfusion; no transfusion-related adverse reactions were observed among the 100 patients. Conclusion Patients with solid tumors demonstrated a distinct Hb increase following the transfusion of FTDRBC. No statistically significant difference in ΔHb was observed between the two scenarios, and the need for subsequent transfusions remained controllable within 72 hours post-transfusion. Prolonged storage (with a median duration of 928 days) did not compromise transfusion efficacy. No evidence of liver or kidney function impairment, nor coagulation dysfunction, was detected, and no transfusion-related adverse reactions were reported. In contexts of limited blood resources or scarce rare blood type reserves, FTDRBC exhibits favorable safety and efficacy profiles in perioperative transfusion management for patients with solid tumors.

Key words: Frozen-thawed deglycerolized red blood cells, Solid tumors, Patient blood management, Transfusion safety, Perioperative anemia

中图分类号: